read drug distribut industri
con abc less clear abc press releas morn
key take-away today earn call pharmedium seem
primari variabl relat abc guidanc come street view
midpoint obvious compani specif contrast manag
indic exclud pharmedium distribut segment
saw mid singl digit ebit growth vs report compani expect
see fairli similar trend continu core drug distribut oper
howev note addit volum like major contributor abc posit
distribut comp ex-pharmedium pharmedium color pg note
factor guidanc price brand gener price outlook
expect brand inflat mid-singl digit would
slightli wit manag also note
brand econom tie ff deal separ gener deflat end
buy-sid deflat trend manag expect
gener deflat mirror saw notion today
stabil gener deflat rang hope precursor improv
deflat trend normal level believ histor
rang state longer break gener deflat move forward
guidanc metric collect price variabl larg mirror peer distributor
indic modest posit ahead earn thursday
trim number pt lower ep account
continu pharmedium issu term cadenc manag expect ep
slightli back half year see much better profit
growth given lap full pharmedium headwind lower pt
price-to-earnings lower ep estim
maintain ew rate
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
lower usd
return equiti ttm
link barclay live interact chart
equal weight gain
share via largest custom walgreen
compani continu face headwind throughout
relat gener price deflat
believ persist hamper ep growth
upsid case see modest multipl expans
gener price deflat come better fear
would lead improv ep
downsid case see continu persist
gener deflat continu problem
pharmedium bring compani peer
group
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
color pharmedium assumpt
management factor three specif scenario pharmedium busi
tailwind see flat profit y/i signific headwind recal memphi
facil essenti close open part management
indic low end ep guidanc rang pharmedium
neg impact overal compani profit growth would flat contributor
midpoint manag unsur memphi facil re-open
commit re-open facil fda provid feedback current
expect pharmedium busi either tailwind increment headwind
ep forecast assum flat contribut year-over-year
growthmid singl digit oper expens growthmid singl digit growthdistribut servic op profit growthlow mid singl digit growthoth op profit growthhigh singl digit growthoper profit growthlow mid singl digit interest y/yadj effect tax changebrand inflationmid-singl digit inflationgener deflationsimilar tail end stabl nowshar ep y/i barclay corp
amerisourcebergen revenu profit model
 annual revenu model mil abcabcabcabcrevenu revenueabdc drug specialti distribut global commerci servic anim growthabdc drug specialti distribut global commerci servic anim total revsabdc drug specialti distribut global commerci servic anim annual gross profit mil abcabcabcabcgross profit gross profit formula pharma distribut strateg global global commerci servic anim incom gross growthpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmnmtotal gross gp margin press releas pharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmnmtotal gross profit annual oper profit mil abcabcabcabcoper profit ebit ebitpharma distribut strateg global global commerci servic anim incom growthpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmnmtotal ebit ebit marginpharma distribut strateg global global commerci servic anim incom ebit barclay corp
 quarterli incom statement mil ep ep ep distribut sell oper addback check excl intang asset ens rate check ep fulli dilut share growth distribut sell per barclay corp
 annual revenu model mil abcabcabcrevenu revenueabdc drug specialti distribut global commerci servic anim growthabdc drug specialti distribut global commerci servic anim total revsabdc drug specialti distribut global commerci servic anim annual gross profit mil abcabcgross profit gross profit formula pharma distribut strateg global global commerci servic anim incom gross growthpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmtotal gross gp margin press releas pharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmtotal gross profit annual oper profit mil abcabcabcoper profit ebit ebitpharma distribut strateg global global commerci servic anim incom growthpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmtotal ebit ebit marginpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmtotal ebit barclay corp
 annual incom statement distribut sell oper addback check excl intang asset ens rate interest ens check ep fulli dilut share growth distribut sell per barclay corp
steve valiquett herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
